Literature DB >> 2820649

Progressive mucocutaneous herpes simplex infection due to acyclovir-resistant virus in an immunocompromised patient: correlation of viral susceptibilities and plasma levels with response to therapy.

B Bean1, C Fletcher, J Englund, S N Lehrman, M N Ellis.   

Abstract

Rapidly progressive disease due to acyclovir-resistant herpes simplex has not been described. We report such a case and detail successful patient management using viral sensitivities and plasma acyclovir levels to guide therapy. Response was correlated with plasma levels above those inhibiting viral growth by 50% (ID50) in vitro.

Entities:  

Mesh:

Substances:

Year:  1987        PMID: 2820649     DOI: 10.1016/0732-8893(87)90005-8

Source DB:  PubMed          Journal:  Diagn Microbiol Infect Dis        ISSN: 0732-8893            Impact factor:   2.803


  8 in total

Review 1.  Resistance of herpesviruses to antiviral drugs.

Authors:  P A Chatis; C S Crumpacker
Journal:  Antimicrob Agents Chemother       Date:  1992-08       Impact factor: 5.191

Review 2.  Antiviral therapy: current concepts and practices.

Authors:  B Bean
Journal:  Clin Microbiol Rev       Date:  1992-04       Impact factor: 26.132

3.  Continuous infusion of high-dose acyclovir for serious herpesvirus infections.

Authors:  C V Fletcher; J A Englund; B Bean; B Chinnock; D M Brundage; H H Balfour
Journal:  Antimicrob Agents Chemother       Date:  1989-08       Impact factor: 5.191

4.  In vitro and in vivo characterization of herpes simplex virus clinical isolates recovered from patients infected with human immunodeficiency virus.

Authors:  E L Hill; G A Hunter; M N Ellis
Journal:  Antimicrob Agents Chemother       Date:  1991-11       Impact factor: 5.191

5.  Therapy for genital herpes in immunocompromised patients: a national survey. The Herpes Simplex Advisory Panel.

Authors:  A Scoular; S Barton
Journal:  Genitourin Med       Date:  1997-10

Review 6.  Persistent herpes simplex virus infection and mechanisms of virus drug resistance.

Authors:  H J Field
Journal:  Eur J Clin Microbiol Infect Dis       Date:  1989-08       Impact factor: 3.267

7.  Comparative activity of various compounds against clinical strains of herpes simplex virus.

Authors:  G Andrei; R Snoeck; P Goubau; J Desmyter; E De Clercq
Journal:  Eur J Clin Microbiol Infect Dis       Date:  1992-02       Impact factor: 3.267

Review 8.  What clinicians need to know about antiviral drugs and viral resistance.

Authors:  R L Hodinka
Journal:  Infect Dis Clin North Am       Date:  1997-12       Impact factor: 5.982

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.